Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CArdiag: [18F]Florbetaben PET Imaging in Cardiac AL Amyloidosis
NCT05184088Phase 3Completed
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Jan 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of florbetaben in cardiac amyloidosis, amyloid light chain amyloidosis and transthyretin amyloidosis (ATTR), sponsored by Lantheus Holdings, Inc. Primary endpoint: Sensitivity and specificity of visual assessment at 12 weeks. Started Jan 2023; status: completed.
02
Drugs
florbetaben
03
Conditions
cardiac amyloidosisamyloid light chain amyloidosistransthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT05184088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184088.